Marzhan Kanafina

Marzhan Kanafina

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2025 in Eurasian Journal of Applied Biotechnology
Verified
Journal Article
Open access
PDF file
DJD.A. Junussova
D.A. Junussova
ASA.M. Sadykov
A.M. Sadykov
MKMarzhan Kanafina
Marzhan Kanafina
ДШДарья Шарова
Дарья Шарова
DID. Issa
D. Issa
Bacterial lysates are widely used today as immunomodulatory agents that enhance the effectiveness of antibacterial therapy through synergistic interactions with antibiotics. The aim of this study was to evaluate the pharmacological properties of a bacterial lysate obtained from antibiotic-resistant strains of opportunistic microorganisms such as Acinetobacter baumaniі, Klebsiella pneumoniae SCAID PND1-2022 (246), and Pseudomonas aeruginosa SCAID PHRX1-2019 to assess its potential in combating the growing problem of antimicrobial resistance. The study analyzed the properties of the lysate and its effects on the body using in vivo studies at doses of 300.0 and 500.0 mg/kg. No signs of acute toxicity were observed, suggesting that this substance is safe for use. Furthermore, destroyed bacterial cells retain the ability to induce a specific immune response, stimulating immune system activation. Given the inherent resistance of bacterial strains to antibiotics, it can be concluded that the use of bacterial lysate promotes the development of an adaptive immune response directed against highly resistant pathogens, including superbugs.

25 June 2024 in Eurasian Journal of Applied Biotechnology
Verified
Journal Article
Open access
PDF file
SAS.S. Anuarbekova
S.S. Anuarbekova
AJArdak Jumagaziyeva
Ardak Jumagaziyeva
DAD.K. Amangeldinova
D.K. Amangeldinova
ДШДарья Шарова
Дарья Шарова
MKMarzhan Kanafina
Marzhan Kanafina
ASA.M. Sadykov
A.M. Sadykov
One of the problems in global practical medicine is antibiotic-resistant strains. The problem is that pathogens are resistant to a number of antibacterial drugs and this makes treatment difficult, which can be long and/or ineffective. One solution is to develop drugs based on bacterial lysates. In this article, the objects of study are producers of extended spectrum β-lactamases - Enterobacteriaceae, Acinetobacter, Pseudomonas, Staphylococcus, Haemophilus, Streptococcus. We assessed the survival, antibiotic resistance and biological compatibility of 25 microbial cultures. Cultures have acceptable viability numbers reguired for industrially valuable strains: more than 106 CFU/ml (109 – 1010 CFU/ml). Antibiotic resistance to various groups of is antibiotics was studied: carbapenems, fluoroguinolones, cephalosporins, macrolides, aminoglycosides, penicillins, chloramphenicols. The choise of antibacterial drugs is based on the freguent use of these antibiotics. The spectrum of antibiotic resistance of each strain is different, from one antibiotic (Ps. aeruginosa 13) to ten antibiotics (S. pneumoniae 5). Cultures are resistant to amoxicillin, ampicillin, benzylpenicillin, erythromycin and cephalosporins. The strains are mostly biocompatible with each other and have antibiotic resistance to a number of antibacterial drugs.

6 August 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
SASandugash Anuarbekova
Sandugash Anuarbekova
ASAzamat Sadykov
Azamat Sadykov
DADilnaz Amangeldinova
Dilnaz Amangeldinova
MKMarzhan Kanafina
Marzhan Kanafina
ДШДарья Шарова
Дарья Шарова
YKYerkanat Kanafin
Yerkanat Kanafin
Biotechnological research increasingly focuses on developing new drugs to counter the rise of antibiotic-resistant strains in hospitals. This study aimed to create bacterial lysates from antibiotic-resistant pathogens isolated from patients and medical instruments across hospital departments. Identification was performed based on morphological, cultural, and biochemical characteristics, as well as 16S rRNA gene sequencing using the BLAST algorithm. Strain viability was assessed using the Miles and Misra method, while sensitivity to eight antibacterial drug groups and biosafety between cultures were evaluated using agar diffusion. From 15 clinical sources, 25 pure isolates were obtained, and their phenotypic and genotypic properties were studied. Carbohydrate fermentation testing confirmed that the isolates belonged to the genera Escherichia, Citrobacter, Klebsiella, Acinetobacter, Pseudomonas, Staphylococcus, Haemophilus, and Streptococcus. The cultures exhibited good viability (109–1010 CFU/mL) and compatibility with each other. Based on prevalence and clinical significance, three predominant hospital pathogens (Klebsiella pneumoniae 12 BL, Pseudomonas aeruginosa 3 BL, and Acinetobacter baumannii 24 BL) were selected to develop a bacterial lysate consortium. Lysates were prepared with physical disruption using a French press homogenizer. The resulting product holds industrial value and may stimulate the immune system to combat respiratory pathogens prevalent in Kazakhstan’s healthcare settings.